We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Eurofins Expands its Genomic Activities

Eurofins Expands its Genomic Activities

Eurofins Expands its Genomic Activities

Eurofins Expands its Genomic Activities

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Eurofins Expands its Genomic Activities"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Eurofins has announced that this week, three companies offering genomic services (e.g. custom production of synthetic nucleic acid, DNA analysis, proteomic services) in Germany, Japan and the USA have joined the Eurofins Group.

With about 200 employees these companies achieved a turnover of over € 20 million in 2006 and should contribute positively to the result of the Eurofins Group from 2008 onwards.

A number of molecular biology methods have been developed over the past 25 years based on the availability and affordability of custom synthetic nucleic acids such as DNA-amplification, DNA-sequencing, SNP-analysis, gene synthesis and genotyping.

Custom sequences of synthetic nucleic acid can now be produced within 24 hours and are used for the analysis of genetic fragments derived from natural samples in order to analyze their structure and potential mutation. These molecular biology methods have a growing usage in many sectors of the industry including food and feed safety, environmental control, pharmaceutical drug and diagnostic development. They are also one of the main tools currently used in life science research.

Molecular-biological techniques are used to develop new generations of drugs in clinical research. They enable optimization of the research by taking into consideration genetic differences in individuals, improving effectiveness and reducing side effects. Synthetic nucleine acids are further utilized in clinical diagnostics and also the agricultural industry to discover metastases, viral infections and contamination of food.

“Through these acquisitions we will, together with our new partners, improve our market penetration in the area of molecular-biological research”, said Dr. Gilles Martin, CEO of Eurofins.